3-methoxy-N-[2-(4-morpholinyl)ethyl]benzamide | 349110-59-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methoxy-N-[2-(4-morpholinyl)ethyl]benzamide
• 英文别名: 3-methoxy-N-[2-(morpholin-4-yl)ethyl]benzamide；3-methoxy-N-(2-morpholin-4-ylethyl)benzamide
• CAS: 349110-59-4
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: GDTDCOKFSIHHNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(2-氨基乙基)吗啉 、 间甲氧基苯甲酰氯 以 二氯甲烷 为溶剂， 以78%的产率得到3-methoxy-N-[2-(4-morpholinyl)ethyl]benzamide
  参考文献：
  名称：

  Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the Acanthocheilonema viteae Product ES-62 Prevents Development of Collagen-Induced Arthritis

  摘要：

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,

  DOI：

  10.1021/jm401251p

文献信息

• Practical povidone iodine catalyzed transamidation from primary amides and amines
  作者：Jian Wang、Jiangmeng Ren、Yun-Peng Zhu、Xue-Qin Sun、Peng-Fei Hu、Xin Mu、Bu-Bing Zeng

  DOI：10.1016/j.tetlet.2022.154312

  日期：2023.2

  Non-harmful Povidone iodine (PVP-I) was applied in the transamidation to gain N-substituted amides from various primary amides and amines. Diverse aromatic, heterocyclic and aliphatic primary amides/amines were applied in our developed method and more than 45 N-substituted amides were obtained with excellent yields in most cases. Several drugs such as Melatonin and Efaproxiral were successfully acquired

  将无害的聚维酮碘 (PVP-I) 应用于转酰胺基反应，以从各种伯酰胺和胺中获得N-取代的酰胺。在我们开发的方法中应用了多种芳香族、杂环族和脂肪族伯酰胺/胺，在大多数情况下以优异的收率获得了超过 45 种 N-取代的酰胺。成功获得了褪黑激素和依法普西拉等几种药物，其性能优于先前报道的结果。
• BET-PROTEININHIBITORISCHE DIHYDROPYRIDOPYRAZINONE
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2935260A1

  公开（公告）日：2015-10-28
• [DE] BET-PROTEININHIBITORISCHE DIHYDROPYRIDOPYRAZINONE<br/>[EN] BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES<br/>[FR] DIHYDROPYRIDOPYRAZINONES INHIBITRICES DE PROTÉINE BET
  申请人：BAYER PHARMA AG

  公开号：WO2014095774A1

  公开（公告）日：2014-06-26

  Die vorliegende Erfindung betrifft BET-proteininhibitorische, insbesondere BRD4-inhibitorische Dihydropyridopyrazinone der allgemeinen Formel (I) in der A, X, R1, R2, R3, R4, R4, R6, R7 und n die in der Beschreibung angegebenen Bedeutungen haben, Intermediate zur Herstellung der erfindungsgemäßen Verbindungen, pharmazeutische Mittel enthaltend die erfindungsgemäßen Verbindungen sowie deren prophylaktische und therapeutische Verwendung bei hyper-proliferativen Erkrankungen, insbesondere bei Tumorerkrankungen. Desweiteren betrifft diese Erfindung die Verwendung von BET-Proteininhibitoren in viralen Infektionen, in neurodegenerativen Erkrankungen, in inflammatorischen Krankheiten, in atherosklerotischen Erkrankungen und in der männlichen Fertilitätskontrolle.
• Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the <i>Acanthocheilonema viteae</i> Product ES-62 Prevents Development of Collagen-Induced Arthritis
  作者：Lamyaa Al-Riyami、Miguel A. Pineda、Justyna Rzepecka、Judith K. Huggan、Abedawn I. Khalaf、Colin J. Suckling、Fraser J. Scott、David T. Rodgers、Margaret M. Harnett、William Harnett

  DOI：10.1021/jm401251p

  日期：2013.12.27

  In spite of increasing evidence that parasitic worms may protect humans from developing allergic and autoimmune diseases and the continuing identification of defined helminth-derived immunomodulatory molecules, to date no new anti-inflammatory drugs have been developed from these organisms. We have approached this matter in a novel manner by synthesizing a library of drug-like small molecules based upon phosphorylcholine, the active moiety of the anti-inflammatory Acanthocheilonema viteae product, ES-62, which as an immunogenic protein is unsuitable for use as a drug. Following preliminary in vitro screening for inhibitory effects responses, a sulfone-containing phosphorylcholine analogue (11a) was selected for testing in collagen-induced arthritis (CIA). Testing revealed that 11a was as effective as ES-62 in protecting DBA/1 mice from developing CIA and mirrored its mechanism of action in downregulating the TLR/IL-1R transducer, MyD88. 11a is thus a novel prototype for anti-inflammatory drug development. on relevant macrophage cytokine an in vivo model of inflammation,